PAA21 DEVELOPMENT OF A COST-UTILITY MODEL FOR COMPARING GINA STEP 3 ASTHMA MEDICATIONS BASED ON UTILITY AND SAFETY DATA DERIVED FROM A LARGE HEAD-TO-HEAD TRIAL OF MONTELUKAST AND SALMETEROL
Nov 1, 2007, 00:00 AM
10.1016/S1098-3015(10)65413-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)65413-7/fulltext
Section Title :
Section Order :
572
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65413-7&doi=10.1016/S1098-3015(10)65413-7